Hyperfine, Inc.
HYPRNasdaqHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $12.9M | $11.0M | $6.8M | $1.5M | $294,000 |
| Operating income | −$37.1M | −$43.2M | −$48.1M | −$73.9M | −$64.9M | −$23.5M |
| Net income | −$35.6M | −$40.7M | −$44.2M | −$44.2M | −$64.9M | −$23.4M |
| Total assets | $55.3M | $58.9M | $94.2M | $134.1M | $202.5M | $71.5M |
| Total liabilities | $14.3M | $9.9M | $9.8M | $10.3M | $16.2M | $4.3M |
| Equity | $41.0M | $49.0M | $84.4M | $123.7M | $186.2M | −$61.1M |
| EPS (diluted) | $-0.43 | $-0.56 | $-0.62 | $-1.04 | $-17.57 | — |
| Shares out. | 81.8M | 72.4M | 71.3M | 70.4M | 3.7M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −273.4%
- Net margin
- −262.3%
- Return on equity
- −86.8%
- Return on assets
- −64.4%
- Return on capital (ROCE)
- −85.2%
- Liabilities / assets
- 25.8%
- Debt / equity
- 0.35×
- Book value / share
- $0.50
- Revenue growth (YoY)
- 5.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -16.31distress
- Accruals / assets
- −13.8%clean
- Beneish M-Score
- -3.48normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Hale BrettOfficer — CFO and CAO | May 26, 2026 | Sell | 6,047 | $1.65 |
| Teisseyre ThomasOfficer — Chief Operating Officer | May 26, 2026 | Sell | 6,047 | $1.65 |
| Hale BrettOfficer — CFO and CAO | Mar 31, 2026 | Grant | 330,000 | $0.00 |
| Teisseyre ThomasOfficer — Chief Operating Officer | Mar 31, 2026 | Grant | 330,000 | $0.00 |
| Sainz MariaOfficer — President and CEO | Mar 31, 2026 | Grant | 750,000 | $0.00 |
| Teisseyre ThomasOfficer — Chief Operating Officer | Mar 23, 2026 | Sell | 24,188 | $1.21 |
| Hale BrettOfficer — CFO and CAO | Mar 23, 2026 | Sell | 24,188 | $1.21 |
| Teisseyre ThomasOfficer — Chief Operating Officer | Feb 13, 2026 | Sell | 821 | $1.11 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.6M | 2.0 | +54.4% |
| Apr 30, 2026 | 1.0M | 1.3 | -11.5% |
| Apr 15, 2026 | 1.1M | 3.9 | -15.3% |
| Mar 31, 2026 | 1.4M | 2.0 | +8.0% |
| Mar 13, 2026 | 1.3M | 2.2 | +0.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 21, 2026
- Results of operationsMay 12, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleMar 18, 2026
- Results of operationsMar 18, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Entered a material agreement · Other material eventDec 29, 2025
- Results of operationsNov 13, 2025
- Entered a material agreement · Other material eventOct 16, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.